Alerts will be sent to your verified email
Verify EmailNATCOPHARM
Natco Pharma
|
Orchid Pharma
|
Concord Biotech
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
US DMF Filings
|
55.0 . | n/a | 20.0 . |
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
51.0 . | n/a | n/a |
Number of ANDA's Approved By USFDA
|
41.0 . | n/a | n/a |
Domestic Sales Growth - YoY
|
31.2 % | n/a | n/a |
R&D as a % of Total Sales
|
8.0 % | n/a | 3.47 % |
Financials
|
|||
5 yr Average ROE
|
12.01 % | -7.68 % | 19.98 % |
5yr average Equity Multiplier
|
1.19 | 0.59 | 1.34 |
5yr Average Asset Turnover Ratio
|
0.44 | 0.38 | 0.48 |
5yr Avg Net Profit Margin
|
22.3 % | -6.96 % | 30.93 % |
Price to Book
|
3.42 | 4.86 | 12.81 |
P/E
|
14.17 | 45.68 | 72.24 |
5yr Avg Cash Conversion Cycle
|
55.67 Days | 49.91 Days | 7.8 Days |
Inventory Days
|
103.24 Days | 112.74 Days | 81.4 Days |
Days Receivable
|
93.53 Days | 105.72 Days | 103.56 Days |
Days Payable
|
180.2 Days | 255.1 Days | 178.94 Days |
5yr Average Interest Coverage Ratio
|
37.72 | 0.47 | 139.29 |
5yr Avg ROCE
|
15.05 % | -4.58 % | 25.38 % |
5yr Avg Operating Profit Margin
|
34.37 % | 10.74 % | 47.04 % |
5 yr average Debt to Equity
|
0.07 | -0.45 | 0.06 |
5yr CAGR Net Profit
|
2.11 % | -7.77 % | 7.28 % |
5yr Average Return on Assets
|
10.04 % | -2.51 % | 14.95 % |
Shareholdings
|
|||
Promoter Holding
|
49.71 % | 69.84 % | 44.08 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.84 % | -28.23 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
-5.37 % | 15.18 % | -0.43 % |
Natco Pharma
|
Orchid Pharma
|
Concord Biotech
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|